Is Traws Pharma, Inc. overvalued or undervalued?

As of 14 November 2025, Traws Pharma, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued, particularly when considering its P/E ratio of 0, EV to EBIT of 0.14, and a remarkably high ROE of 939.05%. In comparison to peers, Catalyst Biosciences, Inc. is deemed expensive with a P/E of 110.04, while Elutia, Inc. is classified as risky with an EV to EBITDA of -5.54.
Despite the attractive valuation metrics, Traws Pharma has faced significant challenges, as evidenced by its year-to-date return of -75.56%, contrasting sharply with the S&P 500's positive return of 14.49% during the same period. This stark difference highlights the market's skepticism regarding the company's future prospects, despite its strong valuation ratios.